 Less brittle even in low humidity(≤1% moisture content)  Fast dissolution (No change in dissolution profile under stress conditions) and soluble in water at room temperature.  No cross linking.  Lower water vapor permeability than Gelatin capsule.(Gelatin>PEG-Gelatin>HPMC)  Low static electricity and light protected.  No Millard reaction with fillings.  Not substrate for protease.  High tolerance to temperature  Chemical inactivity and solubility at room temperature.  In these type of capsules powder, tablet, granules, pellets, liquids and semisolids are filled.  Suited to automatic capsule filling machines.
QUALI-V®-I:
A New Key for Dry Powder Inhalers 
PULLULAN CAPSULES:
 Water-soluble polysaccharide  Derived by bacterial fermentation from corn.  Widely use in Japan  They are odorless, tasteless, and completely biodegradable  Used in production of foods, pharmaceuticals and cosmetics.  The film formation properties of Pullulan are similar to gelatin.  Dried capsules are comparatively weak in physical strength.
 Requires water to act as a film plasticizer, which may have a negative effect on active ingredients.  Only one supplier of the raw material  Does not show any meaningful advantages over hypromellose  Pullulan is very stable and well-characterized, and has achieved wide regulatory acceptance with its proven safety record.  Its generally use for those people who are vegetarians, diabetics and patients with restricted diets.  It is 100% natural they are Vegetable origin, No chemical modification, Non-GMO, Starch-free, Preservative-free, Gluten-free.
PVA CAPSULES:
 PONDAC Capsule (name)
 Insoluble drugs can be dissolved in solvents such as macrogol 400, being filled in capsules.  The bioavailability of insoluble drugs can be improved very much.  The oxygen permeability of PVA copolymer capsule is significantly low.  The gelatin capsule was developed in the 19th century.  The HPMC capsule was developed in the 20th century.  The PONDAC capsule is the hope for the 21st century
STARCH CAPSULES:
 Made from potato starch and represent a direct alternative to hard gelatin capsule.  Manufactured by the injection moulding technique developed by Capsugel (Capill®).  Offers advantages like.
• pH independent dissolution
• Suitable for enteric coating
• Tamper evident
• Produced from non-animal derived ingredients  Consists cap and body; which are sealed together at the time of filling to prevent separation.  Sealing is achieved by applying a hydro alcoholic solution to inner section of the cap, immediately prior to its being placed on to the body.  Different size capsules are manufactured ( number 0, 1, 2, 3, 4) by changing the mold.  Officially recognized in USP 23 and NF 18
ENTERIC STARCH CAPSULES:
 Overcome coating problems encounter during coating of HGC.
 Coating of starch capsules appear to be less problematic because of the smooth seal, coupled with the higher bulk density of capsules, which provide for a more uniform coating bed.  Stability of coated starch capsule evaluated.  Eg. TARGIT®
VCaps®:
 Two-piece capsules made from cellulosic raw materials that satisfy vegetarian and cultural needs  easy to swallow  effectively mask taste and odor  allow product visibility  Vcaps capsules are also starch-free, gluten-free and preservative-free, and meet the strict dietary needs of customers that choose a vegetarian lifestyle.  They are also Kosher and Halal certified.
 Vcaps vegetable capsules are manufactured in a GMP facility that meets ISO 9000 certification criteria.
GELATIN/PEG CAPSULES:
 Reduce the brittleness of standard gelatin capsules when exposed to a low-moisture content thus making the capsules more compatible to hygroscopic formulations or moisture-sensitive ingredients 
PRESS FIT® GELCAPS:
 a unique dosage form consisting of a high-gloss gelatin coating that encases a caplet core.
 Press-Fit gelcaps combine the best qualities of a gelatin capsule with the density of a tablet, creating an exciting new dosage form that can be custom engineered to meet specific product performance criteria.  The elegant, geometric shape of Press-Fit gelcaps is distinct in the marketplace.
 The high gloss finish and extensive selection of color combinations provide additional opportunities for unique trade dress and enhanced consumer recognition.  The outside gelatin shell is taste-free,  Safe and effective utilization in oral dosage applications.
Manufactured by exclusive cold-shrink process on a special filling and coating machine.
LICAPS®:
 Two-piece gelatin capsules that have been specially designed to be sealed for secure containment of liquids and semi-solids.  In combination with a liquid fill, provides an attractive and viable dosage form, particularly for poorly soluble compounds.  The use of hot melts is also viable with Licaps, as they may be filled at temperatures up to 70° C.
POSILOK®:
is the registered trademark for the locking system used by Qualicaps.
It ensures that the contents reach the consumer intact, and are protected at all times from external contamination.
MINICAPSULES:
The amount of material needed for testing is often very small(in mg) Qualicap's Minicapsule(size9) provides a dependable method of delivering the material directly into animal's stomach with minimal waste & great flexibility in dosing & available in gelatin &HPMC option Some of the essential first pre-clinical tests that examine safety and pharmacokinetic factors are carried out on rodents or guinea pigs. The amount of material needed for testing is often very small (milligram quantities). Qualicap's Minicapsule (size 9) provides a dependable method of delivering material directly into the animal's stomach with minimal waste. These small, size 9 capsules can be filled with small, yet precise doses.
Scientists have great flexibility in dosages because each capsule is filled individually and can be adjusted to the weight of the individual rodent. Minicapsules are available in both gelatin and hypromellose (HPMC) options.
COATING METHOD FOR SOFT GELATIN CAPSULES WITH IMPROVED STABILITY .
Adding 10-90% ethanol into mixture of HPMC 20-150parts, Tween80 8.5-25vol parts, Titanium white powder 7.5-25wt parts, Talc powder 7.5-25wt parts, 2%chocolate brown solution, 7.5-25wt parts, castor oil 15-40 vol parts to obtain coating solution, regulating flow rate of coating material at 25-40°C under relative moisture of 20-60%.
CLOSED JOINED LENGTH
8.40mm +/-0.30mm
It can produce soft capsules with slower aging speed.
INNOVATIONS IN CAPSULE SYSTEM:
To provide modified release • PORT CAPSULE TECHNOLOGY:
eg.Pseudoephedrine delayed release
HYDROPHILIC SANDWHICH(HS) CAPSULES:
 Simple and time delayed probe capsule  Based on a capsule within a capsule, in which the inter capsular space was filled with a layer of hydrophilic polymer (HPMC).
 This effectively created a " Hydrophilic Sandwich " between two gelatin capsule  When the outer capsule dissolved, the sandwich of HPMC formed a gel barrier layer that provided a time delay before fluid could enter the inner capsule and cause drug release 
1.L-OROS HARD CAP:
 The drug layer and the osmotic engine are encased in hard capsule which is surrounded by the rate controlling semi permeable membrane.
 A barrier layer composed of an inert substance separates the drug layer from osmotic engine.  A delivery orifice is laser drilled at the opposite end of the osmotic engine providing an outlet for the drug.
2.L-OROS SOFT CAPSULES:
Manufacturing barrier layer, osmotic engine, and a semi permeable membrane in order.  A delivery orifice in drilled through semi-permeable membrane,osmotic engine and barrier layer.  When the osmotic engine expands it compresses the soft capsule and the drug drug formulation is pushed out through the delivery orifice.
3.DELAYED LIQUID BOLUS SYSTEM:
 Delivers the pulse of the liquid drug.  The system consists of the placebo delay layer, a liquid drug layer, an osmotic engine all encased by a subcoat and then surrounded by semi-permeable membrane.  The delivery orifice is drilled on the placebo layer of the system.  When the osmotic engine expands, the placebo is released first delaying the drug release.  Delay in drug release can be srom 1-10 hours depending on the permeability of the rate controlling membrane and the size of the placebo layer.
PULSIN CAP:
Used for pulsatile drug delivery.
In general consists of insoluble capsule body and a soluble capsule cap.
 First concept : separation of a plug form an insoluble capsule body.
 It comprised of a water permeable body prepared from a water-swellable hydrogel cross linked PEG polymer  A swelling agent mixed with the drug, was filled into the internal cavity of capsule body and a plug was used to seal the contents into the internal cavity.
 Upon oral administration by the patient, cap dissolves. Water diffuses through capsule body. Swelling causes plug to move in upward direction causing drug release.
 Water diffusion into the core through semi permeable through semi-permeable membrane is controlled by:
Hydrogel composition and Wall thickness of the capsule.
PLUG, CROSS LINKED HYDROGEL

SECOND CONCEPT:
 capsule body is made of gelatin coated with ethyl cellulose.
 In the presence of fluid, the plug swelled at a controlled rate that was independent of the nature of pH of the medium.
 As the plug swells it attains frustroconical shape and it gets slowly pulled out of the capsule.
 Pulse time is controlled by:
The length of the plug and insertion distance of plug into the capsule.
 Disadvantage: not adopted for large scale manufacturing because of high cost.
DRUG FORMULATION PERMEABLE CROSS LINKED HYDROGEL SWELLING AGENT
THIRD CONCEPT:
 Here in this approach in place of hydrogel plug, simple erodible compressed tablet is placed.
 This overcomes the need for the precise dimensional tolerance between capsule and plug for sliding mechanism of the plug.
CHEWABLE SOFT GELATIN CAPSULE ENCAPSULATING LIQUID FILL
 Chewable SGC require mixture of gelatin having different bloom values. 
INNER CAP TECHNOLOGY:
 The combination example consists of a high potency insoluble active in a lipid emulsion, sustained release tablet and a cocktail of two crystalline active materials.
 A combination of release profiles can be incorporated in the system.
 Can deliver incompatible and compatible drugs using different physical phases.
 The combination dosage form consists of a primary HPMC capsule containing an emulsion, pH coated tablet, crystalline filled HPMC capsule and a beadlet filled gelatin capsule. • Potential for Improved Drug Absorption improve oral bioavailability for hydrophilic and lipophilic drugs with low solubility.
Opportunities offered by Multi -Phase Multi-compartment Capsules
• Potential for Reduced Degradation in the GI Tract reduce degradation as well as improve absorption may be especially useful for drugs, for which both low solubility and degradation in the GI tract contribute to a low oral bioavailability.
• Tolerability & Taste
The fact that DGDG, in contrast to phospholipids, is uncharged makes it less prone to cause irritation The favorable taste of Galacticles™ formulations compared to corresponding formulations with phospholipids and synthetic surfactants • Safety
The components of Galacticles™ are natural dietary lipid components found in processed and natural foods.
Preliminary safety studies indicate no toxic effects of oral administration
MIRISHITA JINTAN'S SEAMLESS SOFT GELATIN CAPSULES
-Perfect seamless shapes like a shining pearl.
-Principle: interfacial tension leads our unique dropping technology.
-The inner nozzle, of the concentric double nozzle, ejects core contents and the outer nozzle supplies the heated shell solution.
-through this simultaneous action, the shell solution wraps the core substances.
Extremely homogenous and very small:
No variation in size or weight.
Controllable hardness:
Hardness freely can be controlled by changing the material, water content and thickness of the shell.
Controllable shell thickness:
size can be reduced up to 30microns.
The capsule dissolves quickly. Shell can be filled with 50% or more as compared conventional soft capsule.
The shell is made of a water soluble polymer such as gelatin or agar. 
CAPSULE SHELL QUALITY: SHELL MATERIAL ACID RESISTANCE
SODAS® Technology:
Spheroidal Oral Drug Absorption System is Elan's multiparticulate drug delivery system. Based on the production of controlled release beads, the SODAS®Technology is characterized by its inherent flexibility, enabling the production of customized dosage forms that respond directly to individual drug candidate needs.
It can provide no of tailored drug release profiles, including immediate release of drug followed by sustained release to give rise to a fast onset of action, which is maintained for 24hours. Alternatively the opposite scenario can be achieved and additional option is pulsatile release.
Elan's SODAS® Technology is based on the production of uniform spherical beads of 1-2mm in diameter containing drug plus excipients and coated with product specific controlled release polymers.
The most recent regulatory approvals for a SODAS® based system is the once daily oral dosage forms of Avinza TM ,Ritalin®LA and Focalin®XR.
CODAS® TECHNOLOGY:
A delay of drug action may be required for different reasons. Chronotherapy is an example of when drug release may be programmed to occur after a prolonged interval following administration. Chronotherapeutic Oral Drug Absorption System(CODAS TM Technology) was developed to achieve this prolonged interval.
Verelan® PM product using this Technology is designed to begin releasing Verapamil approximately 4-5hrs post ingestion. Delay is introduced by the level of release controlling polymer applied to the drug loaded beads. The release controlling polymer is a combination of water soluble and water insoluble polymers.
As water from the GIT contacts the polymer coat beads, the water soluble polymer slowly dissolves and the drug diffuses through the resulting pores in the coating.
The water insoluble polymer continues to act as a barrier, maintaining the controlled release of the drug.
When taken at bad time, this controlled onset extended release delivery system enables a max. plasma concentration of verapamil in the morning hours, when blood pressure generally rises from its overnight low.
PRODAS® TECHNOLOGY:
Programmable Oral Drug Absorption System is multiparticulate technology; it combines the benefits of tabletting technology within a capsule.
PRODAS® system is presented as a number of minitablets combined in a hard gelatin capsule. It can be used to pre-program the release rate of a drug. It is possible to incorporate many different mini tablets, each one formulated individually and programmed to release drug at different sites within the GIT.
It is possible to incorporate mini tablets of different sizes so that high drug loading is possible.
PRODAS® technology, by incorporating mini tablets with different release rates, can display the characteristics of no of different conventional dosage forms:
-IR component will mimic conventional formulation.
-Delayed release can provide site/regional release and food resistance.
-Sustained release component provides additional controlled release/protection.
PULSYS TM TECHNOLOGY:
MiddleBrook TM Pharmaceuticals developed PULSYS TM , an oral drug delivery technology that enables once daily pulsatile dosing.
PULSYS TM dosage form is a compressed tablet that contains pellets, designed to release drug at different regions in the GIT in a pulsatile manner. The dosage form is made up of multiple pellet types of varying release profiles that are combined in a proportion so as to produce a constant escalation in plasma drug levels in the early portion of the dosing interval.
The transit property of pellets enhance the overall absorption time window and offer improved bioavailability compared to tablet matrix forms.
Moxatag TM tablets contains amoxicillin and improved bactericidal action in pulsatile manner was observed as compared to standard dosing regimen.
ORBEXA® TECHNOLOGY:
Multiparticulate system that enables high drug loading and provides a formulation choice for products that require granulation.
It produces beads that are of controlled size and density and suitable for formulation as controlled release multiparticulates-using granulation, spheronization and extrusion technique.
The resultant beads can be coated with functional polymer membrane for additional release rate control and may be filled into capsules or provided in sachet form. Process allows for high drug concentration within each bead. The technology is suited for use with sensitive drugs such as proteins.
EURAND MINITABS® TECHNOLOGY:
Minitabs are tiny, approximately 2mm in diameter, cylindrical tablets. Functional membranes may be applied to the tablets to further control release rate.
It offers high drug loading, a wide range of release rate designs, and fine tuning of these release rates.
Capsules containing the Eurand Minitabs® can be opened and the contents used as a sprinkle formulation.
Banner's VersetrolTM Technology:
Novel innovative Technology that provides time controlled release for wide range of drug.
Drug is incorporated in lipophilic or hydrophilic matrix and that is than incorporated in soft gelatin capsule shell.
Technology is versatile because depending on physicochemical property of drug either emulsion/suspension can be developed.
For lipophilic drugs suspension formulation is preferred while for hydrophilic drugs emulsion form is utilized. By applying combination of lipophilic and hydrophilic matrices desire release profile can be achieved. These capsules have highly tunable properties (eg, shear modulus and release rate), which can be selected for different applications, such as personal care, foodstuffs, and home care. A key feature of these capsules is the internal architecture: they have inter-penetrating domains of immiscible fluids (bicontinuity).
The bijel capsules are made of two fluids and hence they are both a gel and an emulsion. The water and oil domains inside the capsules can be used to deliver chemically different active ingredients. The capsules can be designed to release or mix the active ingredients in response to a specific external stimulus.
Cross-linked DNA capsules templated on porous calcium carbonate microparticles:
To prepare hollow microcapsules composed of native DNA, we developed a templating method using porous calcium carbonate microparticles as sacrificial templates. At first, DNA was adsorbed onto calcium carbonate microparticles, and then the adsorbed DNA was covalently cross-linked with each other by using ethylene glycol diglycidyl ether. After the dissolution of the templates, the resultant DNA capsules ranged from 1.5 to 8 μm in diameter, according to ionic strength. The low cross-linked and highly cross-linked DNA capsules exhibited enzymatic degradability and permeability that was dependent on the molecular weight of macromolecular solutes, respectively. This method has the potential to be used for the preparation of various single-component polymer capsules.
